Overview

A Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

Status:
NOT_YET_RECRUITING
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single ascending doses in adults who are affected by obesity.
Phase:
PHASE1
Details
Lead Sponsor:
Fujian Shengdi Pharmaceutical Co., Ltd.